Gene-editing trials are optimistic and Tesla stocks are going ballistic, but first: a cartoon about meme cinema. Here’s the news you need to know, in two minutes or less.
Want to receive this two-minute roundup as an email every weekday? Sign up here!
Crispr-edited cells show promise in first US human safety trial
Initial reports on the safety of the nation’s first in-human test of the disease-fighting potential of Crispr gene editing are here: So far, so good. Research from the University of Pennsylvania and Stanford showed that Crispr-edited cells didn’t cure anyone’s cancer, but they didn’t kill anyone, either, which holds significant promise for the future of Crispr-based medicines.
Tesla is finally cruising, and investors are going for a joyride
Tesla stock has been skyrocketing recently, but the company took a 17 percent hit on Wednesday after it announced the coronavirus outbreak would delay Model 3 deliveries. It was Tesla’s second-worst day on the market—but probably just a minor setback for a company that has seen its stock rise more than 70 percent this year alone.
Fast Fact: 0
That’s how many side-view mirrors Nuro’s R2 self-driving car will have, after federal regulators freed the company from some legal design requirements that no longer apply when human drivers are gone. The exemption is the first of its kind for the self-driving industry.
WIRED Recommends: Backpacks for Work
Whether you’re commuting on your bike with a laptop or schlepping your camera around the mountains, these 12 professional backpacks will help you do the job right.
News You Can Use
Looking to buy a drone? Here’s the best one for most people.
This daily roundup is available as a newsletter. You can sign up right here to make sure you get the news delivered fresh to your inbox every weekday!